LAUSR

Methodology: 280 T2DM patients aged 18-75 years irrespective of their A1c, on standard glucose lowering, lipid lowering and BP lowering therapy were divided into 2 groups, group 1N (105 patients normoalbuminuria UACR 30). Both groups were followed-up for 2 years and assessed every 3-6 months for for renal (creatinine, eGFR, UACR) and CV (BP, BMI, Lipid profile, hs-CRP, NTProBNP) parameters. Patients with history of major surgery, coronary intervention, IHD or hospitalization in last 1 year, eGFR 5.3 were excluded. Data was analyzed using PSPP version 1.0.1 and represented as Mean (SD) and paired t-test was used, P-value of 0.01 was considered to be significant. Results: Baseline treatment characteristics were well matched. For BP, use of ARB was 82.9% (1N) and 96.1% (2M) group, CCB was 35.2% (1N) and 61.2% in (2M) group. At Baseline SBP (2M 139.17±22.35 vs. 1N 131.91 ±14.66, p Conclusion: Patients with eUACR had a significantly elevated SBP, non-HDL cholesterol, and creatinine, compared to nUACR at baseline. Despite CV risk factor optimization systolic-BP remained significantly higher in eUACR group. NTProBNP remained high in both groups although it trended to be slightly elevated in eUACR group although it was statistically NS. Disclosure V. Gupta: None. V. Teli: None.